Shares of MEDNAX, Inc. (NYSE:MD) recorded -0.87% loss during trading session on February 7th, 2019. The script traded as low as $34.59 and last traded at $36.32. 2.41 million shares changed exchanged hands during trading, a drop of -248123.76% from the 30-day average session volume of 969.07K shares. The firm had previously closed at $36.64. The company has $87.48M outstanding shares, a price-to-earnings ratio of 12.28, price-to-earnings-growth ratio of 0.88 and a beta of 0.67. The company has a RSI of 49.28, ATR of 1.05 and a volatility of 4.14% this week. MD has a 52 week low price of $31.68 and a 52 week high price of $63.04.
Investors have identified the tech company MEDNAX, Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around 3.18B, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
MEDNAX, Inc. (MD) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. For MD, the company has in raw cash 54.46 million on their books with 413.74 million currently as liabilities. How the trend is over time is what investors should be concerned about. The company has a healthy balance sheet as their debt profile has been on an incline. In terms of their assets, the company currently has 0 total, with 2.02 billion as their total liabilities. This figure have given the company a good sense of viability under numerous contexts.
MD were able to record 124.2 million as free cash flow during the recently reported quarter of the year, this saw their quarterly net cash flow reduce by 25.74 million. In cash movements, the company had a total of 162.33 million as operating cash flow.
Potential earnings growth for MEDNAX, Inc. (MD)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, MEDNAX, Inc. recorded a total of 896.65 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with 0.03% coming in sequential stages and their sales for the third quarter reducing by -0.02%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 655.88 million trying to sell their products during the last quarter, with the result yielding a gross income of 240.78 million. This allows shareholders to hold on to 87.48M with the revenue now reading 720 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (0.80 cents a share).
Is the stock of MD attractive?
Having a look at the company’s valuation, the company is expected to record 3.78 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on MD sounds very interesting.
In related news, Principal Accounting Officer Pepia John C sold 2,500 shares of the company’s stock in a transaction that recorded on January 22nd, 2019. The sale was performed at an average price of 36.60, for a total value of 91,500. As the sale deal closes, the Principal Accounting Officer Pepia John C now sold 3,500 shares of the company’s stock, valued at 168,641. Also, Chief Financial Officer Lopez-Blanco Vivian sold 13,942 shares of the company’s stock in a deal that was recorded on June 12th, 2019. The shares were sold at an average price of 46.46 per share, with a total market value of 100,590. Following this completion of acquisition, the Principal Accounting Officer now holds 6,516 shares of the company’s stock, valued at 303,374. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.30%.
4 out of 16 analysts covering the stock have rated it a Buy, while 10 have maintained a Hold recommendation on MEDNAX, Inc. stock. 1 analysts has assigned a Sell rating on the MD stock. The 12-month mean consensus price target for the company’s shares has been set at $42.36.